tiprankstipranks
Trending News
More News >
Aziyo Biologics, Inc. Class A (ELUT)
:ELUT
US Market
Advertisement

Aziyo Biologics (ELUT) AI Stock Analysis

Compare
66 Followers

Top Page

ELUT

Aziyo Biologics

(NASDAQ:ELUT)

Rating:51Neutral
Price Target:
$2.00
▼(-4.31% Downside)
The overall stock score reflects significant financial challenges, offset by positive earnings call highlights. While financial instability and valuation concerns weigh heavily, strong product growth and strategic initiatives provide some optimism.
Positive Factors
Financial Stability
Cash on hand is expected to support Elutia until the second half of 2026, providing a stable financial footing for continued operations and growth.
Market Share
EluPro is positioned as a superior product with antibiotic properties and a soft biomatrix for better patient comfort and pacemaker protection, likely to capture significant market share.
Sales Growth
Product uptake for EluPro is robust, with substantial same-center sales growth and over 100 active accounts, indicating strong market acceptance.
Negative Factors
Business Development
The Company also made progress with its litigation related to the divested Orthobiologics business, critical to business development activity.
Product Performance
SimpliDerm was below expectations in Q4 due to partner Tiger working through its reorganization process.

Aziyo Biologics (ELUT) vs. SPDR S&P 500 ETF (SPY)

Aziyo Biologics Business Overview & Revenue Model

Company DescriptionAziyo Biologics (ELUT) is a regenerative medicine company that operates in the healthcare sector, focusing on the development and commercialization of biologic products to improve compatibility between medical devices and the human body. The company's core products include implantable tissues and device-compatible solutions designed for use in cardiology, orthopedics, and other medical fields. Aziyo Biologics aims to enhance healing and integration of medical implants, thereby improving patient outcomes.
How the Company Makes MoneyAziyo Biologics makes money primarily through the sale of its biologic products to healthcare providers and medical device manufacturers. Its revenue model is based on direct sales and distribution agreements, where the company supplies its proprietary solutions that are used alongside medical devices to improve performance and patient compatibility. Significant partnerships with leading medical device companies enhance its market reach and distribution capabilities, contributing to its revenue growth. The company's earnings are also influenced by its ability to innovate and expand its product offerings in response to evolving medical needs and regulatory approvals.

Aziyo Biologics Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: -2.79%|
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth and successful product launches, particularly with EluPro, alongside improved gross margins and progress in litigation settlements. However, challenges remain with SimpliDerm's performance and ongoing litigation issues.
Q2-2025 Updates
Positive Updates
EluPro Commercial Success
EluPro experienced 49% sequential growth this quarter, driven by 7 national GPO contracts and active ordering from 161 hospital systems. EluPro makes up 68% of BioEnvelope revenue, and sales per account are 130% higher compared to CanGaroo.
Awards and Recognition
Elutia received the Edison Award for Innovation in Medical Technology, two Medical Device Network Excellence Awards, and Dr. Michelle Williams won the Medical Device Innovator of the Year award.
BioEnvelope Revenue Growth
BioEnvelope revenue for the quarter increased by 33% year-over-year, reaching about a $14 million run rate, primarily driven by EluPro growth.
Litigation Progress
Elutia settled 97 out of 110 lawsuits stemming from a past product recall, significantly reducing future legal expenses and removing a strategic overhang.
Gross Margin Improvement
Adjusted gross margin increased to 62.4% for Q2, up from 58.4% a year ago, due to operational efficiencies and high margins in the cardiovascular segment.
Negative Updates
SimpliDerm Underperformance
SimpliDerm generated $2 million in revenue this quarter, which is lower than previous quarters, indicating a need for improved performance or strategic partnerships.
Litigation Legacy
Elutia is still dealing with 13 unresolved lawsuits related to a product recall from over four years ago, although progress is being made towards settlement.
Company Guidance
During Elutia's Second Quarter 2025 earnings call, the company provided robust guidance centered on the continued success and expansion of their EluPro product. EluPro saw a remarkable 49% sequential growth this quarter, with active ordering from 161 hospital systems. The company's strategic focus is on increasing the number of hospitals under contract through VACs and GPOs, which directly drives revenue. EluPro now constitutes 68% of the BioEnvelope revenue, with expectations to end the year at a $20 million revenue rate. Elutia also highlighted the upcoming NXT-41 platform for breast reconstruction, targeting a $1.5 billion U.S. market, and emphasized their ongoing strategic opportunities aimed at enhancing their cash position and business development. Gross margin improvements were noted, with the BioEnvelope business achieving a 62.4% adjusted gross margin, up over 4 percentage points from the previous year.

Aziyo Biologics Financial Statement Overview

Summary
Aziyo Biologics is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flows. The balance sheet reflects high leverage and negative equity, while the income statement shows poor operational performance. The cash flow statement reveals a reliance on external financing. These factors combine to suggest a risky financial position with substantial challenges ahead.
Income Statement
25
Negative
Aziyo Biologics has faced a consistent decline in revenue from previous periods, with a negative revenue growth rate from 2021 to 2025. The gross profit margin has decreased considerably from 2020 onwards, highlighting increasing cost pressures. Additionally, the company has been experiencing continuous net losses, leading to negative net profit margins. EBIT and EBITDA margins are also negative, indicating operational inefficiencies.
Balance Sheet
30
Negative
The company exhibits a concerning financial structure with negative stockholders' equity since 2022, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, but high total liabilities suggest significant leverage. Return on equity is negative due to losses. The equity ratio is also negative, reflecting financial instability and risk.
Cash Flow
20
Very Negative
Aziyo Biologics is experiencing negative operating and free cash flows, which have deteriorated over the past years. The operating cash flow to net income ratio indicates cash flow issues, as cash flows do not cover net losses. The company is heavily reliant on financing activities to support operations, posing a risk to sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue23.68M24.38M24.75M23.85M47.39M42.68M
Gross Profit10.58M10.71M11.05M11.64M19.02M20.56M
EBITDA-14.01M-45.89M-31.92M-27.30M-15.72M-12.30M
Net Income-21.32M-53.95M-37.66M-32.90M-24.83M-21.82M
Balance Sheet
Total Assets33.85M36.13M43.43M68.84M67.17M82.81M
Cash, Cash Equivalents and Short-Term Investments8.50M13.24M19.28M16.99M30.39M39.15M
Total Debt28.24M24.74M23.95M39.40M23.24M52.31M
Total Liabilities75.69M82.39M82.03M73.87M53.65M61.98M
Stockholders Equity-41.84M-46.26M-38.60M-5.03M13.52M20.83M
Cash Flow
Free Cash Flow-33.27M-23.31M-22.11M-21.97M-15.99M-14.07M
Operating Cash Flow-32.79M-22.66M-21.76M-21.43M-15.62M-13.44M
Investing Cash Flow-1.03M-474.00K14.21M-540.00K-369.00K-640.00K
Financing Cash Flow24.14M17.09M9.84M9.00M6.71M51.02M

Aziyo Biologics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.09
Price Trends
50DMA
2.02
Positive
100DMA
2.04
Positive
200DMA
2.74
Negative
Market Momentum
MACD
0.02
Negative
RSI
52.40
Neutral
STOCH
57.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELUT, the sentiment is Positive. The current price of 2.09 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 2.02, and below the 200-day MA of 2.74, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.40 is Neutral, neither overbought nor oversold. The STOCH value of 57.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELUT.

Aziyo Biologics Risk Analysis

Aziyo Biologics disclosed 77 risk factors in its most recent earnings report. Aziyo Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aziyo Biologics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$185.76M-52.99%16.55%16.73%
51
Neutral
$7.82B-0.16-39.78%2.19%21.38%-1.56%
51
Neutral
$93.27M149.62%-5.22%82.06%
46
Neutral
$114.70M-49.55%-33.76%17.10%
36
Underperform
$142.71M-61.29%-39.69%
33
Underperform
$274.90M-125.43%-686.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ELUT
Aziyo Biologics
2.09
-1.94
-48.14%
ZNTL
Zentalis Pharmaceuticals
1.99
-1.20
-37.62%
CCCC
C4 Therapeutics
2.61
-4.03
-60.69%
VOR
Vor Biopharma
2.17
1.22
128.42%
KYTX
Kyverna Therapeutics, Inc.
3.85
-4.24
-52.41%

Aziyo Biologics Corporate Events

Private Placements and Financing
Elutia Inc. Amends Credit Agreement with SWK Funding
Neutral
Aug 20, 2025

On August 15, 2025, Elutia Inc. amended its Credit Agreement initially established on August 10, 2022, with SWK Funding LLC and other lenders. The amendment involves capitalizing accrued interest and amendment fees into the principal balance of a $25 million senior secured term loan, potentially impacting the company’s financial obligations and liquidity management.

Shareholder Meetings
Aziyo Biologics Holds Annual Stockholders Meeting
Neutral
Jun 4, 2025

On May 29, 2025, Elutia Inc. conducted its annual meeting of stockholders, with 80.9% of Class A common stock represented. During the meeting, two Class II directors were elected to serve until 2028, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2025